Redeye: Sprint Bioscience Q1 2023 - VADA deal needed
Redeye provides its comment on Sprint Bioscience’s Q1 2023 report, and we judge that the company needs to close a VADA deal in the near future to strengthen its financial position.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/